RXDX Ignyta Inc.

IGNYTA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

WILMINGTON, Del.--(BUSINESS WIRE)--

Rigrodsky & Long, P.A.:

  • Do you own shares of Ignyta, Inc. (NASDAQ CM: RXDX)?
  • Did you purchase any of your shares prior to December 22, 2017?
  • Do you think the proposed buyout is fair?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Roche Holding AG (“Roche”) in a transaction valued at approximately $1.7 billion. Under the terms of the agreement, shareholders of Ignyta will receive $27.00 in cash for each share of Ignyta common stock.

If you own common stock of Ignyta and purchased any shares before December 22, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242, or by e-mail at [email protected].

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
27/12/2017

Underlying

RXDXIgnyta Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ignyta Inc.

 PRESS RELEASE
Free
RXDX IGNYTA INC.

Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 9:00 a.m. Pacific time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A webcast of the presentation will be available during the presentation in the Investors section of the company...

January 4, 2018 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...

January 3, 2018 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodula...

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RXDX-106, a novel oral immunomodulatory agent and TAM inhibitor, in patients with solid tumors. Under this IND, the company intends to initiate the TITAN (Targeted Immunomodulatory TAM ANtagonist) study, a first-in-human, open label, multicenter, dose escalation s...

December 29, 2017 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investi...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...

December 28, 2017 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

IGNYTA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Inves...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Ignyta, Inc. (NASDAQ CM: RXDX)? Did you purchase any of your shares prior to December 22, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) regarding possible...

December 27, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch